Efficacy of curcumin as adjuvant therapy to improve remission in myeloma patients

Not Applicable

Completed

• Conditions: Multiple myeloma; Cancer

• Registration Number: ISRCTN14131419
• Lead Sponsor: PDP (Lembaga Pengelola Dana Pendidikan)

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35919637/ (added 30/12/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2017-06-30
• Study Start: 2019-11-08
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

1. New multiple myeloma patients
2. Aged over 18 years old
3. Ineligible for transplant

Exclusion Criteria

1. Sepsis
2. Severe infection
3. Pregnancy
4. Patients with severe disease (such as acute hepatitis, chronic hepatitis, cirrhosis)
5. Elevation of aspartate aminotransferase (AST) >3 times upper limit normal (ULN)
6. Participated in another study
7. Poor performance status

Study & Design

• Study Type: Interventional
• Study Design: Not specified